CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that are designed to remain inert in healthy tissue but become activated specifically in the tumor microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology. Source
No articles found.
Microbot™, which was founded in 2010 and commenced operations in 2011, became a NA...
Microbot™, which was founded in 2010 and commen...
Aquestive Therapeutics is a specialty pharmaceutical company that advances and com...
Aquestive Therapeutics is a specialty pharmaceu...
Alseres Pharmaceuticals, Inc. is focused on the development of diagnostic and ther...
Alseres Pharmaceuticals, Inc. is focused on the...
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
We are developing nalbuphine ER to treat serious neurologically mediated condition...
We are developing nalbuphine ER to treat seriou...
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, le...
Intra-Cellular Therapies is a biopharmaceutical...
Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...
Merus is a clinical-stage immuno-oncology compa...
Join the National Investor Network and get the latest information with your interests in mind.